All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications

December 10, 2024
By Gary Ritchie
Sharon Flank
News
Article
Pharmaceutical TechnologyPharmaceutical Technology, December 2024
Volume 48
Issue 12
Pages: 22–25

This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.

3D printed pills and drugs, future of medicine. 3D Printing Drugs In Pharmacies. Multi-colored, various drugs, pills, capsules. Pharmaceutical medical concept | Image Credit: © irissca - © irissca - stock.adobe.com

irissca - stock.adobe.com

Before industrialization, pills were formulated by compounding, mixing, rolling, cutting, and finishing for a particular patient. This process remains useful when mass production fails to create a version that works for an individual, whether because the dose is incorrect or an unacceptable ingredient such as an allergen must be avoided. Compounding for a single individual is regulated differently from mass production (1) in every jurisdiction; although, it is worth noting that even trituration via mortar and pestle must be performed using gloved hands, in a clean environment, free of vermin, standing water, and the like (2). Three-dimensional printing (3DP) offers many advantages, particularly for personalized medicine, but, from a legal and regulatory perspective, regardless of specific print technique, it is neither exactly compounding, nor is it exactly mass production. The technology can be used to develop novel drug delivery options, potentially manufactured at scale and thus falling under existing FDA manufacturing regulations. It can be employed for distributed manufacturing, introducing issues of portability that FDA is addressing in its Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) discussions (3). Here the focus is more on point-of-care production, either for a single patient or, potentially, for a small group as in a children’s hospital. Wise regulatory choices can allow 3DP to flourish to patients’ advantage, building on its strengths and, crucially, adding options for better patient care. A focus on the intersection of areas of need (dose customization, polypills, allergen avoidance) with relative simplicity will lead to earlier success.

Discussion

Compositional changes affect bioavailability and cannot be implemented at the point of care, but shape and size variations can be pre-tested, bounded, and made available for the dispensing pharmacist to control. One approach to such bounding is the creation of so-called pharma-inks, pre-formulated but with dosing to be controlled at the point of care; another is the use of cartridges. Neither of these approaches offers allergen avoidance, but it is possible that there will be other intermediate-based offerings that allow limited customization (e.g., from a list of APIs according to a validated formulary). While it is unlikely that 3DP will be as fast as industrial-scale manufacturing such as tableting and capsule-filling, the ease of variation offers advantages whenever changeability is a positive attribute. This paper addresses the interplay of positive variation (e.g., for personalized medicine) and negative variation (i.e., repeatability failure).

3D printing technologies

The variety of 3DP technologies has been discussed in depth, including for drug printing (4). All share several basic commonalities. First, raw materials can be placed in a particular location in a dose form, with the result that geometric features are available to manipulate drug delivery parameters. In conventional manufacturing, coating offers this option, but only in a limited fashion. Second, the raw materials are utilized first in a flowable form (powder, liquid, gel), and then, depending on the method, one or more techniques are used to solidify the resulting dose. In the case of filament-based printing, this is a two-step process, in which a coil of thin filament is first created, generally via hot-melt extrusion, and then fed through a printer so that the shape can be manipulated.

Click here for a PDF of this article.

Click here to view Table I.

Peer-reviewed research

Submitted: July 1, 2024
Accepted: July 15, 2024

References

1. CFR Title 21, 225.1 (Government Printing Office, Washington, DC). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=225.1
2. FDA. Guidance for Industry, on Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug and Cosmetic Act (CDER, July 2014).
3. FDA. CDER Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) Initiative, Distributed Manufacturing and Point-of-Care Manufacturing of Drugs, October 2022.

About the authors

Gary Ritchie, InfraTrac gritchie@infratrac.com, is director of Scientific Affairs at InfraTrac. Sharon Flank*, PhD, sflank@infratrac.com, is CEO at InfraTrac.

*To whom all correspondence should be addressed.

Article details

Pharmaceutical Technology®
Vol. 48, No. 12
December 2024
Pages: 22–25

Citation

When referring to this article, please cite it Ritchie, G.; Flank, S. Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications. Pharmaceutical Technology 2024, 48 (12), 22–25.

Download Issue PDF
Articles in this issue

Head with bulb | Image Credit: ©ShpilbergStudios – stock.adobe.com
Enhancing Quality Through Training
3D printed pills and drugs, future of medicine. 3D Printing Drugs In Pharmacies. Multi-colored, various drugs, pills, capsules. Pharmaceutical medical concept | Image Credit: © irissca - © irissca - stock.adobe.com
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
Human head shape made from a large grid of pins connected with string. Communication technology and mental health concept | Image Credit: © ink drop - Stock.adobe.com
European Biotechs Unlocking Parkinson’s Disease
Future and media concept | Image Credit: ©peshkova - stock.adobe.com
Integrating Advanced Technologies for Pharma Analysis
Lipid nanoparticle siRNA antiviral delivery system, 3D illustration | Image Credit: © Dr_Microbe - © Dr_Microbe - stock.adobe.com
Exploring Opportunities for LNP Delivery in mRNA
3d rendering. Empty blank black metal sphere balance scale on white background. | Image Credit: ©PATARA – stock.adobe.com
Comparability in Accelerated or Stressed Stability Studies Using a Quality Range
Close-up of a microscope lens examining microarray slides, a crucial tool in genomic research and medical diagnostics | Image Credit: © Varunee - Stock.Adobe.com
Leveraging Advancements in Bioanalytical Testing
Landkarte *** Europa | Image Credit: © beugdesign - Stock.adobe.com
Advancing the Precision Oncology Agenda in Europe
High Angle Shot of a Working Desk of a Successful Person in Office with Cityscape Window View. | Image Credit: © Gorodenkoff - stock.adobe.com
Rethinking Drug Pricing
Retro classic typewriter from circa 1950s with sheet of paper and aged books on wooden desk front aquamarine wall background. Nostalgic writer's work place concept. Vintage old style filtered photo | Image Credit: © BrAt82 - stock.adobe.com
New Year, New PTE
Question mark background | Image Credit: © Leigh-Prather - © Leigh Prather - stock.adobe.com
Complying with CGMPs for Sterile Manufacturing
ROSS Model 42N-10 Ribbon Blender | © Charles Ross & Son Company
Ribbon Blenders for Bulk Blending
Datwyler NeoFlex Plungers for large volume biologics | © Datwyler
Coated Plungers for Large Volume Biologics
Recent Videos
Related Content

Coronavirus Covid-19 background - 3d rendering | Image Credit: © Production Perig - stock.adobe.com

EMA Recommends Update to COVID-19 Vaccines for 2025-26 Campaign

Patrick Lavery
May 19th 2025
Article

The LP.8.1 variant of the SARS-CoV-2 virus differs from the JN.1 family that previous vaccines had been designed to target, and has surpassed JN.1 as the variant circulating most widely worldwide.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


Gold winners award with three stars | Image Credit: © sergign - stock.adobe.com

ISPE Announces Six 2025 FOYA Category Winners

Patrick Lavery
May 15th 2025
Article

Six winners and two honorable mentions were revealed at ISPE’s Europe Annual Conference in London.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


Feb 2, 2020 South San Francisco / CA / USA - Genentech headquarters in Silicon Valley; Genentech, Inc., is an American biotechnology corporation which became a subsidiary of Roche in 2009 | Image Credit: © Sundry Photography - stock.adobe.com

Genentech and Roche Expand US Footprint with New North Carolina Manufacturing Facility

Patrick Lavery
May 13th 2025
Article

The proposed $700 million, 700,000-square-foot space will support the companies’ future joint portfolio of next-generation obesity medicines.


Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Piramal Pharma to Invest $90 Million at Kentucky & Michigan Sites

Patrick Lavery
May 12th 2025
Article

The company said the investment is in response not only to customer demand and a belief in the value of US-based innovation, but also because of the trend toward US onshoring brought about by new tariff policies.

Related Content

Coronavirus Covid-19 background - 3d rendering | Image Credit: © Production Perig - stock.adobe.com

EMA Recommends Update to COVID-19 Vaccines for 2025-26 Campaign

Patrick Lavery
May 19th 2025
Article

The LP.8.1 variant of the SARS-CoV-2 virus differs from the JN.1 family that previous vaccines had been designed to target, and has surpassed JN.1 as the variant circulating most widely worldwide.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


Gold winners award with three stars | Image Credit: © sergign - stock.adobe.com

ISPE Announces Six 2025 FOYA Category Winners

Patrick Lavery
May 15th 2025
Article

Six winners and two honorable mentions were revealed at ISPE’s Europe Annual Conference in London.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


Feb 2, 2020 South San Francisco / CA / USA - Genentech headquarters in Silicon Valley; Genentech, Inc., is an American biotechnology corporation which became a subsidiary of Roche in 2009 | Image Credit: © Sundry Photography - stock.adobe.com

Genentech and Roche Expand US Footprint with New North Carolina Manufacturing Facility

Patrick Lavery
May 13th 2025
Article

The proposed $700 million, 700,000-square-foot space will support the companies’ future joint portfolio of next-generation obesity medicines.


Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Piramal Pharma to Invest $90 Million at Kentucky & Michigan Sites

Patrick Lavery
May 12th 2025
Article

The company said the investment is in response not only to customer demand and a belief in the value of US-based innovation, but also because of the trend toward US onshoring brought about by new tariff policies.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.